07:25 AM EST, 01/10/2025 (MT Newswires) -- Pfizer ( PFE ) said Friday that its pivotal phase 3 trial evaluating sasanlimab in combination with Bacillus Calmette-Guerin, or BCG, as treatment for non-muscle invasive bladder cancer achieved its primary endpoint of event-free survival.

The study showed that the combination therapy provided a "clinically meaningful and statistically significant improvement" compared with BCG alone, according to Pfizer ( PFE ).

Prolonged event-free survival provided by the investigational treatment may delay or reduce the need for more aggressive treatment options, said Neal Shore, lead investigator for the trial.

The safety profile of sasanlimab in combination with BCG "was generally consistent" with the known profiles of BCG and PD-1 inhibitors, Pfizer ( PFE ) added.

The company said sasanlimab is also being investigated in combination with its antibody drug conjugate portfolio in advanced solid tumors.